Array Biopharma, Inc. (ARRY) Reports Q1 EPS Loss of $0.06, Sales Beat Expectations
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $5.19 --0%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q1 EPS of ($0.06), $0.13 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $17.38 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Aebi Schmidt Holding AG (AEBI) Reports Q2 results; offers guidance
- McGraw Hill (MH) Tops Q2 EPS by 11c, Beats on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
